ArticleGynecology and minimally invasive therapy
Navigating the Landscape of Uterine Fibroid Treatment Using a Novel Scarless Technology (GYIDE): A Case Report.
Article in Gynecology and minimally invasive therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine fibroids (UFs) affect 70%-80% of women by age 50. Traditional treatments include medical management and invasive surgery. Recent advancements in fibroid treatment introduce less invasive methods like radiofrequency ablation (RFA), microwave ablation, uterine artery embolization, and MR-guided focused ultrasound. Accurate fibroid mapping and electrode placement are major challenges in the case of fibroid ablation. GYIDE, a scarless technology, demonstrates the feasibility for ultrasound-guided transcervical RFA. A 40-year-old woman with multiple intramural fibroids underwent RFA using GYIDE prior to hysterectomy. The procedure involved preoperative ultrasound, three-dimensional fibroid rendering, real-time mapping, and delivering the RFA for UF. Transcervical RFA targeted a 4 cm × 3.5 cm fibroid at 115 W for 5 min under ultrasound guidance. The GYIDE system enabled safe, precise RFA without complications. Intraoperative ultrasound confirmed effective ablation. Postthysterectomy analysis revealed no serosal perforation or thermal damage. The 4 mm navigation arm avoided cervical dilation, reducing discomfort. GYIDE delivers safe and precise transcervical RFA for UFs, with promising potential for expanded applications with advancing research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.